Allergy Therapeutics AI Stock Analysis
Allergy Therapeutics (HHU) AI Stock Analysis
Allergy Therapeutics
(Frankfurt:HHU)
No summary available
Allergy Therapeutics (HHU) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 91.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 58.79K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 0.91
- Revenue Growth
- 5.09%
- EPS Growth
- -1.00%
- Country
- Germany
- Employees
- 584
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Allergy Therapeutics Business Overview & Revenue Model
Company Description
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside dia...
Allergy Therapeutics Peers Comparison
Overall Rating
GB:HIK74Outperform
GB:VLG62Neutral
GB:STX43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | GBP 3.47B | 12.35 | 15.05% | 3.78% | 2.48% | 3.36% | |
| 62Neutral | GBP 82.02M | 15.82 | 7.82% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | GBP 32.23M | -4.04 | 64.57% | ― | 36.19% | 60.75% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:HHU | Allergy Therapeutics | 0.03 | -0.05 | -62.07% | |
| GB:HIK | Hikma Pharmaceuticals | 1675.00 | 168.28 | 11.17% | |
| GB:STX | Shield Therapeutics | 3.05 | -3.50 | -53.44% | |
| GB:VLG | Venture Life | 69.20 | 11.20 | 19.31% | |
| GB:BXP | Beximco Pharmaceuticals Limited Sponsored GDR RegS | 57.50 | 18.80 | 48.60% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
